13/02/2025 09:29

Cochlear Ltd (COH) $306.69

Hearing implant business COH was the best-performing healthcare name on Wednesday, closing up +1.6%. However, we remain concerned that the share price isn’t factoring in the risks of Moderna’s potential phase III data for a vaccine against human cytomegalovirus, which causes infant deafness.

Read more

04/10/2024 09:24

Cochlear Ltd (COH) $287.70

Read more

27/09/2024 09:13

Cochlear Ltd (COH) $284.21

It’s a surprise in many ways to consider hearing aid business COH as a turnaround stock, but it's down ~5% year-to-date, having corrected 22% from its July high. In August, its FY24 result was a slight ~3% miss, but that can/did prove ugly when the market is long with little disregard for downside risks, i.e.

Read more

16/08/2024 08:47

Cochlear Ltd (COH) $313.00

COH -7.3%: FY24 NPAT of $387mn was a relatively small miss compared to consensus at $399mn, but it caught an optimistic market wrong-footed and sent the hearing implant stock spiralling lower—investors are used to COH beating, not missing.

Read more

16/05/2024 09:19

Cochlear Ltd (COH) $331.80

We haven’t looked at COH since February. At the time, we were neutral, and the stock hasn’t moved since. Moving into the EOFY, we believe the stock will advance with the market and valuation expansion but it's not on our radar following its stellar advance since early 2023, i.e. the best could be behind COH for the foreseeable future.

Read more

19/02/2024 16:56

Cochlear (COH) $327.82

COH -2.01%: the hearing implants company’s 1H was largely pre-announced at a trading update last week, Cochlear pulled back from all-time highs hit on Friday on slight cracks showing in the numbers.

Read more

09/02/2024 09:30

Cochlear Ltd (COH) $304.74

We discussed COH earlier in the week after it was downgraded to a “Sell” by UBS who made some interesting points around the potential for Moderna getting a vaccine approved to treat ~20% of child deafness.

Read more

07/02/2024 09:24

Cochlear Ltd (COH) $287.29

COH uncharacteristically fell almost 7% on Tuesday after influential UBS downgraded the stock to a sell on competition fears after the stock's ~50% advance since 2023. Their main discussion reminded us of the Ozempic et al. fears that sent ResMed (RMD) tumbling in August/September of last year0

Read more

30/11/2023 09:11

Cochlear Ltd (COH) $267.00

The Healthcare Sector has embraced the advance by bonds through November, and we anticipate this improvement over the last 5-weeks will continue into 2024. However, it's still likely to be patchy, as we’ve witnessed through most of 2023. Our preferred scenario is a “risk on” style Christmas rally that will see some less popular names enjoy a rare period of outperformance.

Read more

07/11/2023 09:11

Cochlear Ltd (COH) $US247.29

COH is up +21% so far this year, but interestingly, it hasn’t caught our attention as much as more battered names over the last week's turnaround – one week doesn’t make a summer. If we are correct and bond yields drift/fall into Christmas we believe the best performance within the Healthcare Secxtor will be enjoyed by stocks that really struggled in the first three quarters.

Read more